Clinical Trial Update: Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on acamprosate for ALS with C9orf72 hexanucleotide repeat expansion (ACALS). The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• acamprosate (acamprosate)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 1 | Status: ACTIVE_NOT_RECRUITING